

Sage Therapeutics, Inc.  
Form SC 13G  
February 14, 2017  
**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. )\***

SAGE THERAPEUTICS, INC.  
(Name of Issuer)

COMMON STOCK  
(Title of Class of Securities)

78667J108  
(CUSIP Number)

12/31/2016  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.: 78667J108

1.

Names of Reporting Persons:  
OppenheimerFunds, Inc.  
IRS Identification No: 13-2527171

Edgar Filing: Sage Therapeutics, Inc. - Form SC 13G

2. Check the Appropriate Box if a Member of a Group (See Instructions):  
Joint Filing
3. SEC Use Only
4. Citizenship or Place of Organization:  
Colorado
5. Sole Voting Power: 0
6. Shared Voting Power: 1,936,075
- Number of Shares Beneficially Owned by Each Reporting Person With
7. Sole Dispositive Power: 0
8. Shared Dispositive Power: 1,936,075
9. Aggregate Amount Beneficially Owned by Each Reporting Person:  
1,936,075 (beneficial ownership disclaimed pursuant to Rule 13d-4 of the Exchange Act of 1934)
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  
[ ]
11. Percent of Class Represented by Amount in Row (9):  
5.21
12. Type of Reporting Person (See Instructions):  
IA

Item:

Name of Issuer:

1(a) SAGE THERAPEUTICS, INC.

Address of Issuer's Principal Executive Offices:

1(b) 215 FIRST STREET  
CAMBRIDGE MA 02142

Name of Person Filing:

2(a) OppenheimerFunds, Inc.

Address of Principal Business Office or, if none, Residence:

2(b) 225 Liberty Street  
New York, NY 10281

Citizenship:

2(c) Colorado

Title of Class of Securities:

2(d) COMMON STOCK

Edgar Filing: Sage Therapeutics, Inc. - Form SC 13G

CUSIP Number:

2(e) 78667J108

If this statement is filed pursuant to §240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

3  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E)

Amount beneficially owned:

4(a) 1,936,075  
(beneficial ownership disclaimed pursuant to Rule 13d-4 of the Exchange Act of 1934)

Percent of class:

4(b) 5.21

4(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:  
0

(ii) Shared power to vote or to direct the vote:  
1,936,075

(iii) Sole power to dispose or to direct the disposition of:  
0

(iv) Shared power to dispose or to direct the disposition of:  
1,936,075

5 Ownership of Five Percent or Less of a Class:

Ownership of More than Five Percent on Behalf of Another Person.:

6 N/A

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

7 N/A

Identification and Classification of Members of the Group:

8 N/A

Notice of Dissolution of Group:

9 N/A

Certification:

10 By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

**SIGNATURE**

Edgar Filing: Sage Therapeutics, Inc. - Form SC 13G

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

02/14/2017

Date

/s/ Mary Ann Picciotto

Signature

Mary Ann Picciotto, Sr. Vice President and Chief Compliance Officer

Name/Title

If you have questions please contact Judith Gottlieb at (212) 323-4858 or by email at [jgottlieb@ofiglobal.com](mailto:jgottlieb@ofiglobal.com)